Balchem Corporation (BCPC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Balchem Corporation (BCPC) trades at $167.68 with AI Score 89/100 (Grade A+). Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products across various sectors, including nutrition, food, pharmaceuticals, and animal health. Market cap: $5.39B, Sector: Basic materials.
Price live · AI analysis from May 10, 2026BCPC stock analysis for 2026: Analysts have set a consensus price target of $162.00 for Balchem Corporation, suggesting 3.4% downside from the current price of $167.68. The AI MoonshotScore is 89/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
BCPC: 1/1 perspectives are bullish.
How is this calculated? →Balchem Corporation (BCPC) Materials & Commodity Exposure
Balchem Corporation, a specialty chemicals company, focuses on developing and marketing performance ingredients for human and animal nutrition, along with specialty products for healthcare and industrial applications. With a diverse portfolio and global reach, Balchem serves a wide range of markets through its three key segments.
What Is the Investment Thesis for BCPC?
Balchem Corporation presents a compelling investment case based on its diversified product portfolio and exposure to multiple growing markets. With a P/E ratio of 33.0 and a profit margin of 15.0%, the company demonstrates solid profitability. Key growth catalysts include expanding its microencapsulation technology and chelated minerals offerings. The company's ability to innovate and adapt to changing market demands, coupled with its established distribution network, positions it for sustained growth. However, potential risks include fluctuations in raw material costs and increased competition in the specialty chemicals market. Investors should monitor the company's ability to maintain its gross margin of 36.3% and dividend yield of 0.60%.
Based on FMP financials and quantitative analysis
BCPC Key Highlights
- Market capitalization of $5.39B indicates a strong market presence.
- P/E ratio of 33.0 reflects investor expectations of future earnings growth.
- Profit margin of 15.0% demonstrates efficient operations and pricing strategy.
- Gross margin of 36.3% highlights the company's ability to manage production costs effectively.
- Dividend yield of 0.60% provides a modest income stream for investors.
Who Are BCPC's Competitors?
BCPC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ESI Element Solutions Inc. | $42.59 | -2.41% | $10.38B | 68 |
| SSL Sasol Limited | $9.79 | +1.08% | $6.28B | 52 |
| AXTA Axalta Coating Systems Ltd. | $35.01 | -0.28% | $7.49B | 71 |
| EGO Eldorado Gold Corporation | $33.35 | -0.98% | $6.71B | 61 |
| SSRM SSR Mining Inc. | $30.70 | +0.26% | $6.37B | 99 |
| HGRAF HydroGraph Clean Power Inc. | $3.43 | -3.11% | $1.20B | 69 |
| LWLG Lightwave Logic, Inc. | $7.46 | +1.29% | $1.15B | 69 |
| COOSF Carbios SAS | $6.50 | -9.09% | $109.66M | 69 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BCPC's Key Strengths?
- Diversified product portfolio
- Strong market position in specialty ingredients
- Proprietary technologies
- Global distribution network
What Are BCPC's Weaknesses?
- Dependence on raw material prices
- Exposure to regulatory changes
- Limited brand recognition compared to larger competitors
- Potential for supply chain disruptions
What Could Drive BCPC Stock Higher?
- Continued expansion of microencapsulation technology into new applications.
- Increasing demand for chelated minerals in animal nutrition and high-value crops.
- Potential acquisitions of complementary businesses to expand product offerings.
- Growth in the medical device sterilization market driving demand for ethylene oxide.
- Innovation in human nutrition and health leading to new product development.
What Are the Key Risks for BCPC?
- Rich valuation — a P/E of 33.0 runs well above the Basic Materials sector’s ~22x, leaving little room for a miss.
- Fluctuations in raw material costs impacting profit margins.
- Increased competition from larger chemical companies.
- Economic downturns affecting demand for specialty ingredients.
- Regulatory changes impacting the use of ethylene oxide in medical device sterilization.
- Supply chain disruptions affecting the availability of key ingredients.
What Are the Growth Opportunities for BCPC?
- Expansion of Microencapsulation Technology: Balchem can further expand its microencapsulation technology across various applications, including pharmaceuticals, food, and animal nutrition. The global microencapsulation market is projected to reach $12.5 billion by 2028, offering significant growth potential. By investing in R&D and strategic partnerships, Balchem can enhance its market share and develop innovative solutions for targeted drug delivery and nutrient release.
- Increased Adoption of Chelated Minerals: The demand for chelated minerals in animal nutrition and high-value crops is increasing due to their enhanced bioavailability and absorption. Balchem can capitalize on this trend by expanding its chelated mineral product line and targeting new markets. The global chelated minerals market is expected to grow at a CAGR of 6.5% from 2021 to 2028, driven by the need for improved animal health and crop yields.
- Growth in Medical Device Sterilization: The Specialty Products segment, which offers ethylene oxide for medical device sterilization, presents a significant growth opportunity. With increasing healthcare regulations and the growing demand for sterilized medical devices, Balchem can expand its market share by providing reliable and efficient sterilization solutions. The global medical device sterilization market is projected to reach $10.5 billion by 2027.
- Strategic Acquisitions and Partnerships: Balchem can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. By acquiring companies with complementary technologies and market access, Balchem can accelerate its growth and strengthen its competitive position. This includes exploring opportunities in emerging markets and expanding its presence in key regions.
- Innovation in Human Nutrition & Health: Balchem can focus on developing innovative ingredients and solutions for the human nutrition and health market, including functional foods, dietary supplements, and personalized nutrition products. By investing in R&D and collaborating with food and beverage companies, Balchem can create value-added products that meet the evolving needs of consumers. The global functional foods market is expected to reach $275 billion by 2025.
What Opportunities Does BCPC Have?
- Expansion into new geographic markets
- Development of innovative products and solutions
- Strategic acquisitions and partnerships
- Increasing demand for specialty ingredients in emerging markets
What Threats Does BCPC Face?
- Increased competition from larger chemical companies
- Fluctuations in raw material costs
- Economic downturns affecting demand
- Changes in consumer preferences and regulations
What Are BCPC's Competitive Advantages?
- Specialized product portfolio with niche applications.
- Strong relationships with key customers.
- Proprietary technologies, including microencapsulation and chelation.
- Established distribution network and global reach.
What Does BCPC Do?
Balchem Corporation, founded in 1967 and headquartered in New Hampton, New York, develops, manufactures, and markets specialty performance ingredients and products. The company operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment provides ingredients for the food and beverage industry, including spray dried and emulsified powders, liquid flavor delivery systems, and microencapsulation solutions. This segment also offers human-grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment focuses on enhancing animal health and productivity by providing microencapsulated products and chelation technology for nutrient absorption. The Specialty Products segment offers ethylene oxide for healthcare sterilization and propylene oxide as a fumigant for controlling insects and microbiological spoilage in various food products. Balchem sells its products through a direct sales force, independent distributors, and sales agents, serving the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets globally.
What Products and Services Does BCPC Offer?
- Develops and manufactures specialty performance ingredients.
- Offers solutions for human nutrition and health.
- Provides products for animal nutrition and health.
- Supplies ethylene oxide for medical device sterilization.
- Markets propylene oxide as a fumigant.
- Offers chelated minerals for high-value crops.
- Provides microencapsulation solutions for various applications.
How Does BCPC Make Money?
- Develops and manufactures specialty ingredients and products.
- Sells products through a direct sales force, independent distributors, and sales agents.
- Generates revenue from three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
- Focuses on innovation and customization to meet specific customer needs.
What Industry Does BCPC Operate In?
Balchem Corporation operates within the specialty chemicals industry, which is characterized by innovation, customization, and a focus on specific applications. The market is driven by increasing demand for performance ingredients in the food, nutrition, and healthcare sectors. Balchem competes with companies like Element Solutions Inc. (ESI), Sasol Limited (SSL), and Axalta Coating Systems Ltd. (AXTA). The industry is experiencing growth due to rising health awareness and the need for advanced sterilization solutions. Balchem's diversified product portfolio and global reach position it well to capitalize on these trends.
Who Are BCPC's Key Customers?
- Food and beverage companies
- Pharmaceutical companies
- Animal feed manufacturers
- Healthcare providers
- Agricultural producers
Net buyingInsider Activity
Over the past six months, Balchem Corporation insiders filed 20 SEC Form 4 transactions — 8 sales and 12 purchases. On net that is roughly 54K shares acquired (about $3.8M) — insiders putting money in tends to read as conviction.
FY2026 estForward Outlook
Wall Street analysts project Balchem Corporation revenue of about $1.11B for fiscal 2026, with EPS near $5.24. The estimate reflects 3 contributing analysts.
F-Score 9/9Financial Health
Balchem Corporation's Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 10.13 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 12%Key Financial Metrics
Return on equity for Balchem Corporation stands at 12.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.3%, showing how much profit it generates from its asset base. BCPC trades at a trailing price-to-earnings ratio of 33.01, above the Basic Materials sector average of ~22x. Its free cash flow yield is 3.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.0%, the inverse of the P/E and a quick read on earnings relative to price.
Balchem Corporation (BCPC) Valuation Context
Valued at $5.39B, BCPC is classified as a mid-cap stock. Relative to its peer group, BCPC's quantitative score of 89/100 is above the peer average of 70/100.
BCPC Revenue & Earnings Trend
In Q1 2026, BCPC generated $270.7M in top-line revenue, marking a sequential increase of 2.7%. The company recorded net income of $40.3M, with diluted EPS of $1.25. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Basic Materials. Across the four most recent quarters, BCPC averaged $1.22 in diluted EPS.
Company Profile
Balchem Corporation operates in the Chemicals - Specialty industry within the Basic Materials sector. It is headquartered in Montvale, US. The company is led by CEO Theodore Lee Harris. BCPC has traded publicly since 1986.
BCPC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diversified product portfolio
- Strong market position in specialty ingredients
- Proprietary technologies
- Global distribution network
Bear Case
- Dependence on raw material prices
- Exposure to regulatory changes
- Limited brand recognition compared to larger competitors
- Potential for supply chain disruptions
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $271M | $40M | $1.25 |
| Q4 2025 | $264M | $39M | $1.21 |
| Q3 2025 | $268M | $40M | $1.24 |
| Q2 2025 | $255M | $38M | $1.17 |
Based on FMP financials and quantitative analysis
BCPC Latest News
-
Balchem Corporation to Participate in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026
globenewswire.com · Jun 26, 2026
-
Balchem Corporation to Participate in the Wells Fargo Industrials Conference on June 10, 2026
globenewswire.com · May 27, 2026
-
Are Options Traders Betting on a Big Move in Balchem Stock?
Yahoo! Finance: BCPC News · May 19, 2026
-
Should Balchem’s Q1 2026 Earnings Jump and Buyback Activity Require Action From Balchem (BCPC) Investors?
Yahoo! Finance: BCPC News · May 14, 2026
BCPC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BCPC.
Price Targets
Consensus target: $162.00
BCPC MoonshotScore
What does this score mean?
The MoonshotScore rates BCPC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Balchem Corporation to Participate in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026
Balchem Corporation to Participate in the Wells Fargo Industrials Conference on June 10, 2026
Are Options Traders Betting on a Big Move in Balchem Stock?
Should Balchem’s Q1 2026 Earnings Jump and Buyback Activity Require Action From Balchem (BCPC) Investors?
Leadership: Theodore Lee Harris
CEO
Theodore Lee Harris serves as the CEO of Balchem Corporation. His background includes extensive experience in the specialty chemicals and ingredients industry. He has held various leadership positions, demonstrating expertise in strategic planning, operational excellence, and business development. His career reflects a strong focus on driving growth and innovation within the organization.
Track Record: Under Theodore Lee Harris's leadership, Balchem Corporation has focused on expanding its product portfolio and strengthening its market position. Key achievements include strategic acquisitions and partnerships, as well as investments in research and development. The company has also focused on improving operational efficiency and enhancing customer relationships, contributing to sustained growth and profitability.
Common Questions About BCPC (Basic Materials)
What does Balchem Corporation do?
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for various industries, including human nutrition, animal nutrition, and healthcare. The company operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Its products include microencapsulated ingredients, chelated minerals, and ethylene oxide for medical device sterilization. Balchem aims to provide innovative solutions that enhance the performance and value of its customers' products.
What do analysts say about BCPC stock?
Analyst coverage of Balchem Corporation (BCPC) typically focuses on its growth prospects, profitability, and competitive positioning within the specialty chemicals industry. Key valuation metrics include the P/E ratio, profit margin, and gross margin. Analysts often consider the company's ability to innovate and expand its product portfolio as drivers of future growth. The consensus view is generally positive, reflecting expectations of continued growth and profitability, but investors should conduct their own due diligence.
What are the main risks for BCPC?
The main risks for Balchem Corporation include fluctuations in raw material costs, increased competition from larger chemical companies, and potential economic downturns affecting demand for its products. Regulatory changes, particularly those impacting the use of ethylene oxide in medical device sterilization, also pose a risk. Additionally, supply chain disruptions and changes in consumer preferences could impact the company's performance. Effective risk management and diversification are crucial for mitigating these potential challenges.
What are the key factors to evaluate for BCPC?
Balchem Corporation (BCPC) holds an AI score of 89/100 (high). P/E: 33.0x vs the S&P 500's ~20-25x. Analysts target $162.00 (-3%). Not financial advice.
How frequently does BCPC data refresh on this page?
BCPC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BCPC's recent stock price performance?
Balchem Corporation (BCPC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BCPC overvalued or undervalued right now?
Balchem Corporation (BCPC) trades at 33.0x earnings. Analysts target $162.00 (-3%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BCPC?
Before investing in Balchem Corporation (BCPC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.